Maximizing resources to study an uncommon cancer: E2C2—Epidemiology of Endometrial Cancer Consortium

被引:0
|
作者
Sara H. Olson
Chu Chen
Immaculata De Vivo
Jennifer A. Doherty
Virginia Hartmuller
Pamela L. Horn-Ross
James V. Lacey
Shannon M. Lynch
Leah Sansbury
V. Wendy Setiawan
Leo J. Schouten
Xiao Ou Shu
机构
[1] Memorial Sloan-Kettering Cancer Center,Department of Epidemiology and Biostatistics
[2] Fred Hutchinson Cancer Research Center,Program in Epidemiology, Division of Public Health Sciences
[3] University of Washington,Department of Epidemiology, School of Public Health and Community Medicine
[4] University of Washington,Department of Otolaryngology: Head and Neck Surgery, School of Medicine
[5] Brigham and Women’s Hospital,Channing Laboratory, Department of Medicine
[6] Harvard Medical School,Department of Epidemiology
[7] Harvard School of Public Health,Epidemiology & Genetics Research Program, Division of Cancer Control and Population Sciences
[8] National Cancer Institute,Hormonal and Reproductive Epidemiology Branch, Division of Cancer Epidemiology and Genetics
[9] Northern California Cancer Center,Department of Preventive Medicine, Keck School of Medicine
[10] National Cancer Institute,Department of Epidemiology, GROW – School for Oncology and Developmental Biology
[11] University of Southern California,Vanderbilt Epidemiology Center
[12] Maastricht University,Department of Medicine
[13] Vanderbilt Institute of Medicine and Public Health,undefined
[14] Vanderbilt University Medical Center,undefined
[15] Vanderbilt-Ingram Cancer Center,undefined
来源
Cancer Causes & Control | 2009年 / 20卷
关键词
Endometrial cancer; Epidemiology;
D O I
暂无
中图分类号
学科分类号
摘要
Endometrial cancer affects more than 40,000 women a year in the U.S. While the association of this disease with high body mass index and sex steroid hormones is well known, there are many questions about etiology that have not been resolved. Little is known about the genetic basis for risk associated with hormones or obesity, other common genetic factors associated with risk, or gene–environment interactions. E2C2, the Epidemiology of Endometrial Cancer Consortium, was formed in 2006 to provide a collaborative environment for addressing these questions by pooling data from existing studies. This allows for investigations of uncommon risk factors, risk for rare histologic subtypes, and associations within strata that cannot be achieved in individual studies. This report describes the establishment of the consortium, ongoing projects that demonstrate the advantages of collaborative efforts, and challenges faced. Overall, the consortium promises to provide an important means of furthering our knowledge about this cancer.
引用
收藏
页码:491 / 496
页数:5
相关论文
共 50 条
  • [31] Risk of endometrial cancer after RRSO in BRCA 1/2 carriers: a multicentre cohort study
    Helena Pla-Juher
    Marta Pardo
    Àngel J. Izquierdo
    Esther Darder
    Anna Carbó
    Elisabet Munté
    Sara Torres-Esquius
    Judith Balmaña
    Concepción Lázaro
    Joan M. Brunet
    Maria-Pilar Barretina-Ginesta
    Clinical and Translational Oncology, 2024, 26 : 1033 - 1037
  • [32] Platinum-free interval and response to platinum retreatment or lenvatinib/pembrolizumab in patients with recurrent endometrial cancer: A real-world endometrial cancer molecularly targeted therapy consortium cohort study
    Haight, Paulina J.
    Sanchez, Marilyn
    Thomas, Samantha M.
    Smitherman, Carson
    Cosgrove, Casey
    Bae-Jump, Victoria
    Crafton, Sarah
    Hacker, Kari
    Ko, Emily
    Krivak, Thomas
    Lara, Olivia
    Moore, Kathleen
    Mullen, Mary M.
    Pothuri, Bhavana
    Thaker, Premal H.
    Washington, Christina
    Arend, Rebecca
    Corr, Bradley
    Duska, Linda
    Jackson, Amanda
    Konecny, Gottfried E.
    Wright, Jason
    Secord, Angeles
    Backes, Floor
    GYNECOLOGIC ONCOLOGY, 2025, 194 : 98 - 104
  • [33] Proteomic analysis in endometrial cancer and endometrial hyperplasia tissues by 2D-DIGE technique
    Ceylan, Yasin
    Akpinar, Gurler
    Doger, Emek
    Kasap, Murat
    Guzel, Nil
    Karaosmanoglu, Kubra
    Kopuk, Sule Yildirim
    Yucesoy, Izzet
    JOURNAL OF GYNECOLOGY OBSTETRICS AND HUMAN REPRODUCTION, 2020, 49 (02)
  • [34] Phase 2 trial of pegylated liposomal doxorubicin in advanced endometrial cancer
    Pedro F. Escobar
    Maurie Markman
    Kristine Zanotti
    Kenneth Webster
    Jerome Belinson
    Journal of Cancer Research and Clinical Oncology, 2003, 129 : 651 - 654
  • [35] EMX2 is Downregulated in Endometrial Cancer and Correlated With Tumor Progression
    Qiu, Haifeng
    Yan, Qin
    Luo, Xin
    Zhang, Huijuan
    Bao, Wei
    Wan, Xiaoping
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY, 2013, 32 (02) : 193 - 198
  • [36] Expression of NRP-1 and NRP-2 in Endometrial Cancer
    Oplawski, Marcin
    Dziobek, Konrad
    Grabarek, Beniamin
    Zmarzly, Nikola
    Dabrus, Dariusz
    Januszyk, Piotr
    Brus, Ryszard
    Tomala, Barbara
    Boron, Dariusz
    CURRENT PHARMACEUTICAL BIOTECHNOLOGY, 2019, 20 (03) : 254 - 260
  • [37] Annexin-A2 as predictor biomarker of recurrent disease in endometrial cancer
    Alonso-Alconada, Lorena
    Santacana, Maria
    Garcia-Sanz, Pablo
    Muinelo-Romay, Laura
    Colas, Eva
    Mirantes, Cristina
    Monge, Marta
    Cueva, Juan
    Oliva, Esther
    Soslow, Robert A.
    Angeles Lopez, Maria
    Palacios, Jose
    Prat, Jaime
    Valls, Joan
    Krakstad, Camilla
    Salvesen, Helga
    Gil-Moreno, Antonio
    Lopez-Lopez, Rafael
    Dolcet, Xavier
    Moreno-Bueno, Gema
    Reventos, Jaume
    Matias-Guiu, Xavier
    Abal, Miguel
    INTERNATIONAL JOURNAL OF CANCER, 2015, 136 (08) : 1863 - 1873
  • [38] The role of lipocalin-2 serum levels in the diagnostics of endometrial cancer
    Cymbaluk-Ploska, Aneta
    Chudecka-Glaz, Anita
    Pius-Sadowska, Ewa
    Machalinski, Boguslaw
    Sompolska-Rzechula, Agnieszka
    Kwiatkowski, Sebastian
    Menkiszak, Janusz
    CANCER BIOMARKERS, 2019, 24 (03) : 315 - 324
  • [39] Phase 2 trial of pegylated liposomal doxorubicin in advanced endometrial cancer
    Escobar, PF
    Markman, M
    Zanotti, K
    Webster, K
    Belinson, J
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2003, 129 (11) : 651 - 654
  • [40] PP2A: A Promising Biomarker and Therapeutic Target in Endometrial Cancer
    Remmerie, Michiel
    Janssens, Veerle
    FRONTIERS IN ONCOLOGY, 2019, 9